Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.

[powerpress]

Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.

[powerpress]

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the POINTBREAK trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.

[powerpress]

Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta. 

[powerpress]

Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

The last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta.

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]